Saturday Opinion: In its petition for certiorari, Amgen painted a picture of a Federal Circuit run amok. However, the dichotomy presented by Amgen in its petition for certiorari is a false one
The company’s latest win means that its second highest selling drug will not face US competition for a decade
New policy statement likely to target pay-for-delay deals and sham litigation
18 November 2022
The second instalment of the joint IAM-Docket Navigator US litigation report focuses on the most contentious technology centres in 2022’s third quarter
18 November 2022
Selling revenue streams is an increasingly important way of monetising pharma innovations
16 November 2022
While WTO member states have expressed general sympathy for the goal to provide broad access to vaccine technology during the pandemic, Germany continues to favour patent protection over compulsory licensing.
16 November 2022
District Court decision could mean plaintiffs have more power to control speed and scope of US litigation
14 November 2022
Head of Singapore-based startup reflects on the importance of patents in ensuring its products are proprietary and unique
10 November 2022
District Court in Delaware rebuffs company’s attempt to deny liability in the latest development of the increasingly complex mRNA patent wars
08 November 2022
Surprise decision to hear Amgen’s appeal follows Solicitor General advice not to grant certiorari
07 November 2022
Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line
04 November 2022
Tips on winning in the courtroom plus case law and compliance guidance
02 November 2022
Unlock unlimited access to all IAM content
